Menu ×

HEALTHCARE & PHARMACEUTICAL

Alpha-2 Receptor Agonists Market Segmentation by Use (Hypertension, Attention-Deficit/Hyperactivity Disorder (ADHD), Pain & Panic Disorders, ICU & Procedural Sedation, and Others); and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) – Global Demand Analysis and Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Alpha-2 Receptor Agonists Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • April 2021: Merck Sharp & Dohme Corp. completed the acquisition of Pandion Therapeutics, making it a wholly-owned subsidiary of Merck.

  • April 2021: Pfizer Inc. announced that it had acquired Amplyx Pharmaceuticals, Inc. This acquisition has provided the company the opportunity for advancing its proficiency and deep heritage in treating infectious diseases.

  • October 2020: Mylan N.V. and Pfizer Inc. announced that they had received authorization from the U.S. Federal Trade Commission for proposed combination of Mylan and Upjohn Inc. This transaction sharpens their focus on innovative medicines and breakthroughs in the global healthcare market.  

Global Alpha-2 Receptor Agonists Market Highlights 2022-2030

The global alpha-2 receptor agonists market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2022-2030. The growing prevalence of hypertension and associated disorders, along with the increasing applications of alpha-2 receptor agonists are expected to fuel the progress of this market in the coming years. Along with this, the increasing elderly population and change in lifestyle patterns have given way to the prevalence of various metabolic disorders among people on a global scale, which is expected to lead to an increase in demand for drugs specialized in their treatment. Alpha-2 receptor agonists are increasingly being adopted for treatment as they can reduce blood pressure by inhibiting sympathetic activity in the brain, which in turn is anticipated to drive market growth in the future. The growth of the market can also be attributed to factors such as the rising consumption of unhealthy food, and growing alcohol and tobacco intake on a global level. Furthermore, rising number of incidences of hypertension in lower income nations is expected to provide growth opportunities to the market in the forecast period. According to the data collected from World Health Organization, it was estimated that in 2019, 1.13 billion people globally had hypertension, of which two-thirds of people were living in low and middle-income regions.

Global-Alpha-2-Receptor-Agonists-Market-Overview

The market is segmented on the basis of use into hypertension, attention-deficit/hyperactivity disorder (ADHD), pain & panic disorders, ICU & procedural sedation, and others, out of which, the hypertension segment is anticipated to grab the largest share by the end of 2030 on account of high prevalence of hypertension worldwide. Moreover, the increase in consumption of unhealthy food which is one of the major risk factors for hypertension, is also projected to contribute to the growth of the segment during the forecast period. Additionally, on the basis of distribution channel, the hospital pharmacies segment in the global alpha-2 receptor agonists market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that a considerable portion of the population around the world with hypertension and associated disorders tend to choose hospital facilities for treatment. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Global-Healthcare-Expenditure-per-Capita

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Alpha-2 Receptor Agonists Market Regional Synopsis

Geographically, the global alpha-2 receptor agonists market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the increasing incidence of hypertension-related disorders and growing penetration of alpha-2 receptor agonists in the region. Furthermore, the market in North America is evaluated to occupy the largest share in terms of revenue during the forecast period, owing to the rise in prevalence of attention deficit/hyperactivity disorder (ADHD), accompanied by the presence of leading market players in the region. Along with this, North America also leads in terms of advancements in clinical research, which is also expected to contribute to the region’s market growth in the near future. Alternatively, the market in Europe is also anticipated to occupy a significant share on account of the increasing prevalence of cardiovascular diseases and rising awareness about hypertension in the region. As per the data published in the journal Annals of Global Health in 2020, cardiovascular diseases (CVD) are the leading cause responsible for deaths in Europe and accounts for 45% of the total number of deaths in the region. More than 4 million individuals in Europe suffer death annually from cardiovascular diseases.

Global-Alpha-2%20Receptor-Agonists-Market-Share

The global alpha-2 receptor agonists market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global alpha-2 receptor agonists market includes the following segments:

By Use

  • Hypertension
  • Attention-Deficit/Hyperactivity Disorder (ADHD)
  • Pain & Panic Disorders
  • ICU & Procedural Sedation
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Growth Drivers

  • Increasing Prevalence of Hypertension and Associated Disorders
  • Growing Applications of Alpha-2 Receptor Agonists

Challenges

  • Strict Regulations Regarding Medicine Approval
  • Adverse Effects of Alpha-2 Receptor Agonists such as Sedation & Fatigue

Key Players Dominating the Market

  • Pfizer Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Merck Sharp & Dohme Corp.
  • Mylan N.V.
  • Amneal Pharmaceuticals LLC
  • Unichem Pharmaceuticals Inc.
  • SEQENS Group
  • Teva Pharmaceutical USA, Inc.
  • Ajanta Pharma Ltd.
  • Boehringer Ingelheim GmbH

 

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved